Evidence map›Paper›PMID 35367908›Full record

ArticleSocial science & medicine (1982)2022

Embodied risk for families with Li-Fraumeni syndrome: Like electricity through my body.

Allison Werner-Lin, Rowan Forbes Shepherd, Jennifer L Young, Catherine Wilsnack, Shana L Merrill, Mark H Greene, Payal P Khincha

Registry-linked trialAbstract read
In one paragraph

Article in Social science & medicine (1982), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01443468 (Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01443468 recruitingnot on this map

Clinical, Epidemiologic, and Genetic Studies of Li-Fraumeni Syndrome

TypeobservationalSponsorNational Cancer Institute (NCI)Ran2012Enrolled5,000ConditionsLi-Fraumeni Syndrome, Neoplasms, Tp53 Mutations
3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Proceedings of the seventh annual Women in Melanoma Conference.Therapeutic advances in medical oncology · 2025
    Article
  6. Article
  7. Review
  8. Who Should Have Multigene Germline Testing for Hereditary Cancer?Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Allison Werner-LinSchool of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA, USA; Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA. Electronic address: awer@upenn.edu.
Rowan Forbes ShepherdClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Jennifer L YoungStanford Center for Biomedical Ethics, Stanford University, Stanford, CA, USA.
Catherine WilsnackSteve Hicks School of Social Work, The University of Texas at Austin, Austin, TX, USA.
Shana L MerrillSchool of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA, USA; Hospital of the University of Pennsylvania, Philadelphia, PA, USA.
Mark H GreeneClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.
Payal P KhinchaClinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD, USA.

Funding

Clinical Genetic Studies of Familial and Hereditary Cancer SyndromesZIACP010144 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI SAVAGE, SHARON A. · 2009 to 2025
$111.8M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA CP010144
6 · The paper itself

Abstract

introductionExperiences of illness change the physical body and embodiments, or the ways in which the world and the self are known through the body. When illness is anticipated, such as with inherited cancer predisposition syndromes, risk becomes embodied and shared in family groups. Embodied risk is experienced whether or not symptoms have manifested. To examine how individuals and families with genetic risk experience the world and understand their disease through their bodies, we employ Li-Fraumeni syndrome (LFS) as an exemplar. LFS is a rare, genetic, cancer predisposition syndrome with nearly 100% lifetime cancer risk starting from birth, limited opportunities for prevention, rigorous screening protocols, and early mortality.

methodsForty-five families, including 117 individuals aged 13-81 years, enrolled in the National Cancer Insitute's LFS study (NCT01443468) completed 66 open-ended interviews regarding LFS experiences. An interdisciplinary team used modified grounded theory to explore physical aspects of living with LFS in psychosocial contexts.

findingsThe physicality of living with LFS included constant monitoring of LFS bodies across the family to identify physical change that might indicate carcinogenesis. Cancer screening, risk reduction, and treatment acted as dually protective and invasive, and as an unavoidable features of LFS. Connections between family members with similar embodiments normalized aesthetic changes and supported coping with visible markers of difference. In some circumstances, participants objectified the body to preserve the self and important relationships. In others, intense pain or loss created thresholds beyond which the self could no longer be separated from the body to support coping. DISCUSSION: This paper focuses on Li-Fraumeni syndrome, a familial condition with a well-established genetic identity in which the body-self is experienced in relation to important others, to medical imaging, and to historical experiences with cancer. We expand on theories of embodied risk and inter-embodiment to describe experiences across disease trajectories, with attention to division and union between body, self, and other.

Indexed as

Li-Fraumeni SyndromeEarly Detection of CancerElectricityFamilyGenetic Predisposition to DiseaseHumansCancerDis-embodimentEmbodimentFamilyHereditary cancerLi-Fraumeni syndromeTP53

Identifiers

PMID35367908
PMCPMC9237847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.